<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: ABSTRACT: BACKGROUND: <z:chebi fb="0" ids="36005">Docosahexaenoic acid</z:chebi> (DHA) complexed to human serum albumin (Alb) is neuroprotective after experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we tested using lower concentrations of albumin as part of the complex to achieve neuroprotection </plain></SENT>
<SENT sid="2" pm="."><plain>We found that lower Alb concentrations extend the therapeutic window of protection beyond 5 h after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Sprague-Dawley rats were received 2 h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) </plain></SENT>
<SENT sid="4" pm="."><plain>The behavior was evaluated on day 1, 2, 3 and 7 after MCAo </plain></SENT>
<SENT sid="5" pm="."><plain>In the dose-response study, animals were given either DHA (5mg/kg), Alb (0.63g/kg), DHA-Alb (5mg/kg + 0.32, 0.63 or 1.25 g/kg) or saline, i.v </plain></SENT>
<SENT sid="6" pm="."><plain>3 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo> (n=6-8 per group) </plain></SENT>
<SENT sid="7" pm="."><plain>In the therapeutic window study, DHA-Alb (5mg/kg + 1.25g/kg) was administered i.v. at either 3, 4, 5, 6 or 7 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo> (n=7-9 per group) </plain></SENT>
<SENT sid="8" pm="."><plain>Alb (1.25g/kg) was given at 3 h or 5 h and saline at 3h after <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion </plain></SENT>
<SENT sid="9" pm="."><plain>Seven days after MCAo, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and number of GFAP, ED-1, NeuN, SMI-71 positive cells and vessels were counted </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: Moderate DHA-Alb doses (0.63 and 1.25 g/kg) improved neurological scores compared to albumin-treated rats on days 1, 2, 3 and 7 </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> DHA-Alb doses (0.32, 0.63 and 1.25 g/kg) markedly reduced cortical (by 65-70%), striatal (by 52-63%) and total <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (by 60-64%) compared to native Alb group </plain></SENT>
<SENT sid="12" pm="."><plain>In the therapeutic window study DHA-Alb led to improved neurological score and significant reductions of <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (especially in the cortical or penumbral region), even when treatment was initiated as late as 7 hours after <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAo </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The DHA-Alb complex affords high-grade neurobehavioral neuroprotection in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, equaling or exceeding that afforded by native Alb or DHA, at considerably moderate doses </plain></SENT>
<SENT sid="14" pm="."><plain>It has a broad therapeutic window extending to 7 h after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>Taken together, these finding support the potential clinical feasibility of administering DHA-Alb therapy to patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>